Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Generation of a new class of antiretrovirals targeting HIV-cellular cofactors interactions (HIVINNOV)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,United Kingdom,Netherlands,Spain
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-10-01
End date: 2015-09-30
Duration (months): 36.0
Total project cost (EUR): 10839567.2
EU funding (EUR): 6000000.0
Participants: 7
Project status: CLOSED

Highly active antiretroviral therapy is effective at controlling HIV-1 replication, however emergence and transmission of drug-resistant viruses is increasing, including viruses resistant to the newly developped integrase catalytic inhibitors. It is essential that new antiretrovirals (ARVs) become available. Most ARVs in development belong to the classes of viral enzyme inhibitors. Since HIV requires cellular cofactors for its replication cycle, we aim to develop novel classes of ARVs inhibiting specific virus-host interactions. Because host cell factors mutate rarely, this new class of ARVs should be less vulnerable to resistance. We selected two cellular targets, LEDGF/p75 and Transportin-SR2 (Trn-SR2), cofactors of Integrase (IN) and Capsid (CA) respectively, important for viral integration and nuclear transport. Partners of this consortium, R. Benarous, P. Cherepanov, A. Fassati and S. Emiliani, discovered, with others, these targets and elucidated their structure and function. Partner 1 SME BIODIM (FR), consortium leader, has developped small compound inhibitors of IN-LEDGF interaction. BIODIM compounds have a clear structure activity relationship, nanomolar ARV activity and are based on a new, structurally defined pharmacophore. The objectives of this project are to 1) Advance BIODIM IN-LEDGF inhibitors up to the proof of concept (POC) in man in a phase I/IIa clinical trial with partner 6 J. Gatell (SP) 2) Discover small compounds targeting the Trn-SR2 pathway in HIV-1 infection using a high throughput screening assay validated by partner 2 A. Fassati (UK), determine the pharmacophore by solving the 3D structure of Trn-SR2 with partner 3 P. Cherepanov (UK) and optimize the compounds up to the POC in a humanized mouse model of HIV infection with partner 5, B. Berkhout (NL) 3) Elucidate with partner 4 Emiliani/Saïb (FR) the network of interactions in which Trn-SR2 is involved with CA from uncoating to the pre-integration complex to provide new ARV drug targets.

Keywords: aids,hiv,antiretrovirals,protein-protein interaction inhibitors,drug discovery,phase i/iia clinical trials,ledgf/p75,transportin-sr2,3d protein structure,sumoylation pathway,capsid,hsp90
IMPROvED: IMproved Pregnancy Outcomes by Early Detection; personalized medicine for pregnant women: novel metabolomic and proteomic biomarkers to detect pre-eclampsia and improve outcome. (IMPROVED)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Ireland,Switzerland,Netherlands,Sweden,United Kingdom,Denmark,Netherlands,Germany,United Kingdom,Belgium
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2018-04-30
Duration (months): 66.0
Total project cost (EUR): 7778526.4
EU funding (EUR): 5995390.0
Participants: 12
Project status: CLOSED

1 in 20 first time pregnancies are complicated by pre-eclampsia, the leading cause of maternal death in Europe. No clinically useful screening test exists; consequently, clinicians are unable to offer targeted surveillance or known/emerging preventative strategies. Consortium members have pioneered a personalised medicine approach to identifying blood-borne biomarkers through recent technological advancements, especially in the field of mass spectrometry and the comprehensive mapping of the blood metabolome and proteome. The overall objective of the IMPROvED project is to develop a sensitive, specific, high-throughput and economically viable early pregnancy screening test for pre-eclampsia. This will involve a multicentre, phase IIa clinical study to assess and refine novel and innovative prototype tests based on emerging metabolomic and proteomic technologies developed by SMEs within the consortium. The study will i) recruit 5000 first time pregnant women; ii) establish a high calibre biobank, augmented by accurate clinical metadata; iii) determine whether prototype predictive assays and algorithms translate to the clinical environment; iv) assess potential synergy of a combined metabolomic and proteomic approach and v) progress regulatory approval and development of the selected test into the clinical arena. The application of new technologies to identify ‘at risk’ patients in early pregnancy will allow stratified care with personalized fetal and maternal surveillance, early diagnosis and timely intervention. If an effective test halved antenatal visits and administration of therapies (such as aspirin) to those at risk reduced the incidence of disease by only 20%, potential savings would approximate to €4 billion of the estimated €9 billion/yr spent in Europe providing antenatal care for nulliparous women and treatment for pre-eclampsia. Moreover, an accurate predictive test would be a crucial step in reducing the life-threatening complications of the disease.

Keywords: pregnancy pre-eclampsia maternal mortality perinatal mortality screening tests biomarkers proteomics metabolomics personalised medicine cohort study stratified care antenatal care
Improving the organisation of maternal health service delivery, and optimising childbirth, by increasing vaginal birth after caesarean section (VBAC) through enhanced women-centred care (OPTIBIRTH)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Ireland,Sweden,Netherlands,Finland,United Kingdom,United Kingdom,Germany,Ireland,Italy,Belgium,Italy
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-09-01
End date: 2017-02-28
Duration (months): 54.0
Total project cost (EUR): 3867444.0
EU funding (EUR): 2999263.4
Participants: 11
Project status: CLOSED

Optimal, healthy pregnancy followed by normal birth is the ideal. Caesarean section (CS) doubles the risk of mortality and morbidity (hysterectomy, blood transfusion), and increases the risk of postnatal infection by 5, compared with vaginal birth (WHO Global Survey on Maternal and Perinatal Health). The European Perinatal Health Report (2008) notes “widespread concern” over rising CS rates, which vary from 15% in the Netherlands to 38% in Italy. Much of the rise is due to routine CS following previous CS, despite calls for increased vaginal birth after caesarean (VBAC), which results in less mortality and morbidity and is the preferred option for the majority of women. VBAC rates in Ireland, Germany, and Italy are significantly lower (29-36%) than those in the Netherlands, Sweden, and Finland (45-55%), a difference that equates to 160,000 unnecessary CSs per annum in Europe, at an extra direct annual cost of €156m. Using a cluster randomised trial in Ireland, Germany and Italy, with 15 clusters of 94 women, the OptiBIRTH study will attempt to increase VBAC rates from 33 to 53% through increased women-centred care and women’s involvement in their care, making savings of €2m for every 100,000 births in future. The intervention involves evidence-based education of women and clinicians, introduction of communities of practice (women and clinicians sharing knowledge), opinion leaders, audit and peer review of CSs in each site, and joint decision-making by women and clinicians. The experienced project team developed from an ESF-funded workshop “Promoting Normality in Childbirth” and a COST Action (IS0907: Creating a Dynamic EU Framework for Optimal Maternity Care), and includes 12 partners from 8 countries representing service users, midwifery, obstetrics, epidemiology, sociology, bioethics, health economics and industry (SME). The project, through meaningful patient centred care, will influence EU health policymaking, as advocated by the European Patients’ Forum.

Keywords: organisation of maternity services,women-centred care,normalising birth,vaginal birth after caesarean section,cost-effectiveness
Statistical methods for 3D imaging mass spectrometry in proteomics and metabolomics (3D-MASSOMICS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Sweden,United Kingdom,United States,France,Germany,Germany,Germany,Israel
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2015-10-31
Duration (months): 36.0
Total project cost (EUR): 3527119.27
EU funding (EUR): 2796878.0
Participants: 9
Project status: CLOSED

Since biology is by and large a 3-dimensional phenomenon, 3D imaging has a significant impact on many challenges in life sciences. 3D matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS) is an emerging label-free 3D imaging technology with high potential in proteomics and metabolomics. 3D MALDI-IMS is based on 2D MALDI-IMS, which in the last years has proven its value in metabolomics, glycomics, lipidomics, peptidomics, and proteomics. However, 3D MALDI-IMS cannot tap its full potential due to the lack of computational methods for processing large and complex 3D IMS data. Our main goal is to realise 3D label-free proteomics and metabolomics by providing new statistical methods for the reproducible collection of 3D MALDI-IMS data, and for un- and supervised statistical analysis and interpretation of this data. We will validate our methods in diabetes research, surgical metabolomics, and natural products research. To reach our global goal, we will develop methodologies for reproducible collection of 3D MALDI-IMS data, develop a statistical simulator of MALDI-IMS data and evaluation strategies for statistical methods, develop preprocessing, unsupervised, and supervised methods of statistical analysis of 3D MALDI-IMS data, evaluate the developed methods on simulated and real-life proteomics and metabolomics data, and implement them using efficient graphic processing unit (GPU) architecture. This project is of high importance for research-intensive SME partners, Denator and SagivTech, since it would create a new market segment for them. Expertise of partners in biomedicine and their strong connections to clinical partners ensure adoption of the new methods into clinical practice. The developed methods and protocols can be potentially used in any biomedical application where 3D MALDI-IMS is advantageous such as cancer and diabetes diagnostics, disease pathway elucidation, histopathology, and discovery of biomarkers or antibiotics.

Keywords: 3d maldi imaging mass spectrometry,proteomics,metabolomics,un- and supervised statistical methods,statistical simulation,reproducible collection,quality assurance,evaluation,gpu-implementation
Monitoring innate immunity in arthritis and mucosal inflammation (MIAMI)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Netherlands,Belgium,Netherlands,Ireland,Switzerland
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-02-01
End date: 2016-04-30
Duration (months): 39.0
Total project cost (EUR): 7453018.4
EU funding (EUR): 5703145.0
Participants: 8
Project status: CLOSED

In chronic joint disease, only a subgroup of patients has classical autoantibodies, while the other variants are seronegative arthritis syndromes with a predominance of innate immune disturbances. These forms of joint diseases frequently show extra-articular manifestations of epithelial tissues like skin and gut. On the molecular level, innate immune activation and the release of damage associated molecular pattern proteins (DAMPs) of the S100 family are important mechanisms of initiation and perpetuation. Early diagnosis remains a significant problem, and prediction of disease extension and course is challenging. Despite all efforts we do not have therapies that alleviate the disease and protect from disease progression, damage and long-term disability. The identification of specific inflammatory mechanisms that correlate to patterns of disease characteristics would allow targeted therapeutic approaches. In a comprehensive research approach, MIAMI will establish relevant disease mechanisms and translate finding into novel biomarkers for individual adaptation of therapies (personalised medicine) for seronegative arthritis. Our research strategy leaves retracted ways of genetics and classical autoimmunity; instead we will focus on innate immunity and inflammation. The goals of MIAMI are ambitious and will be reached with cutting-edge research performed by the most excellent researchers in the field, who have been combined to form a multidisciplinary consortium. The choice of the scientific as well as industry partners was entirely based on excellence. Thus, MIAMI brings together the leading teams that are working on mechanisms of innate immunity in arthritis and mucosal inflammation. In summary, MIAMI will significantly contribute to progress on the key questions: Who will be affected by which disease manifestation or complication, how can we use this knowledge to identify the disease, and what will be a meaningful target to treat or even prevent deleterious outcome.

Keywords: seronegative arthritis,spondylarthritis,spondylarthropathies,psoriatic arthritis,juvenile idiopathic arthritis,inflammatory bowel disease,innate immunity,pattern recognition receptors,s100
Supporting Low-cost Intervention For disEase control (SUPPORTING LIFE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Ireland,Sweden,United Kingdom,Malawi,Switzerland,United States,Taiwan, Province of China,Norway
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-05-01
End date: 2017-04-30
Duration (months): 48.0
Total project cost (EUR): 3795877.4
EU funding (EUR): 2835084.0
Participants: 10
Project status: CLOSED

In developing countries, most of the 11 million deaths per year of children under the age five years occur in areas where adequate medical care is not available. In Malawi the under-five mortality rate is 133 per 1,000 live births. First-level health facilities - the closest health care services available to most sick children in developing countries are generally run by local medical physicians. The WHO and UNICEF developed the Integrated Management of Childhood Illness (IMCI) as a strategy to improve childhood survival and disease control. The IMCI strategy uses simple signs and symptoms to assess and classify illness, thus allowing health workers at first-level facilities to identify which children have minor illnesses that need symptomatic treatment. Our proposal addresses the objectives of this call by assisting health care workers through the utilisation of established technologies to circumvent the absence of health infrastructures. It achieves this by utilising the cellular network, patient sensor technologies and decision support systems. Proposed is the Supporting Low-cost Intervention For disEase control (Supporting LIFE) project. It is designed to run in rural settings as a platform for delivering community level interventions to improve and manage disease control. This project has a target age group of children under the age of 5 years. Supporting LIFE targets disease control in a multi-target intervention. It helps to ensure accurate diagnosis for those most affected by malaria/infantile diarrhoea (children under 5 years) and helps to ensure accurate and prompt treatment thus providing accurate real time disease statistics in an area by monitoring symptom trends (e.g. fever/diarrhoea) centrally. It targets other common disease entities which are major causes of morbidity and mortality such as pneumonia thereby increasing its utility. It reduces barriers to care by providing expert systems at low cost to people at their closest point of contact.

Keywords: disease control,data collection,data centre,data quality,data correlation,decision support systems,e-imci,patient sensors,mobile phone,patient healthcare,malaria,improve patient outcomes
Beta cell preservation via antigen-specific immunotherapy in Type 1 Diabetes: Enhanced Epidermal Antigen Delivery Systems. (EE-ASI)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,France,United Kingdom,Netherlands,United Kingdom,Sweden,Israel
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-09-01
End date: 2017-05-31
Duration (months): 57.0
Total project cost (EUR): 7809429.0
EU funding (EUR): 5983871.0
Participants: 8
Project status: CLOSED

Current approaches to improving glycaemic control in type 1 diabetes are centered on increasingly complex insulin delivery systems. However, less than 30% of patients can achieve target levels of glucose control with this approach even in a clinical trial setting and many patients are either unable or unwilling to make the personal commitment required. By contrast, preservation of even small amounts of endogenous insulin production, has been shown to improve glycaemic control, reduce hypoglycaemia, improve quality of life and reduce long-term complications. Importantly, glycemic control in the presence of endogenous beta cell function is not demanding and hence would be effective across the full spectrum of individuals. Antigen specific immunotherapy (ASI) is the preferred approach to beta cell preservation since this avoids the risks of immunosuppression. Attempts at ASI to date although successful in preclinical models have had limited efficacy in humans. There is therefore an urgent need for the development of novel approaches to deliver effective ASI. Our Enhanced Epidermal – Antigen Specific Immunotherapy (EE-ASI) system represents an innovative approach to ASI created by combining technologies brought by our academic and 2 SME partners. A beta cell target T cell epitope (proinsulin C19-A3) will be combined with the tolerogenic cytokine IL-10 and targeted to antigen presenting cells via gold nanoparticles and delivery into the very superficial layers of the skin using microneedles. Validation of manufacture, in vitro and in vivo preclinical efficacy will be demonstrated followed by a phase 1 clinical trial to confirm safety in humans. We anticipate that the EE-ASI system will be less costly, more effective and more acceptable to patients in improving glycaemic control than exogenous insulin replacement. Intellectual property, regulatory and ethical issues will be carefully addressed in order to maximise exploitation of this integrated system for the benefit of the SMEs.

Keywords: type 1 diabetes,immunotherapy,microneedles,nanoparticles,glutamic acid decarboxylase (gad),dendritic cells,langerhans cells,dermal dendritic cells,tolerance,regulatory t cells.
Stem-cell based therapy for kidney repair (STELLAR)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Netherlands,Australia,Italy,United Kingdom,Germany,Netherlands,Netherlands,Italy,Austria,Netherlands
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2017-10-31
Duration (months): 60.0
Total project cost (EUR): 9642381.4
EU funding (EUR): 5998050.0
Participants: 16
Project status: CLOSED

Chronic kidney disease (CKD) affects 8% of the European population and ultimately results in renal failure due to progressive fibrosis. CDK carries a high mortality risk and the number of affected people rises, increasing the demand on renal replacement therapies while the number of available donor organs stays stable. The STELLAR consortium proposes to develop an alternative to renal replacement therapy, based on the repair capacity of newly discovered kidney mesenchymal stromal cells (kMSCs). By injecting kMSC into affected kidneys, we expect to stop kidney fibrosis and induce tissue repair, ultimately leading to the restoration of normal kidney function. The STELLAR consortium will • develop protocols for up scalable, high quality isolation of kMSCs and precisely characterize kMSC function in comparison to other MSCs. • test kMSCs in several murine renal disease models, to study their effects on fibrosis and tissue repair. • discover mechanisms of kidney repair. • invest in developing the technology necessary for up scaled isolation and quality control. The STELLAR consortium combines Australian experts on kMSC isolation and characterisation with European experts on renal failure and compounds the state-of-the-art knowledge, facilities and experience needed to develop and validate this novel form of renal therapy. The inclusion of experienced SMEs, with great technical and scientific know-how about assay and protocol development, further strengthens the consortium and will ensure not only the inclusion of new technology, but also a quick translation from bench to clinical application. In conclusion, the STELLAR consortium is capable of developing and pre clinical validation of this new cellular therapy for CDK, based on a new understanding of stromal cells and fibroblast function, while also providing the technology required for rapid, large scale application of the therapy after clinical validation.

Keywords: stem-cell,chronic kidney disease,renal failure,cellular therapy,kidnet fibrosis